Frontlight ResearchEarly access
Active, not recruitingPhase 3
Follow-up Study for Participants of Jointstem Phase 3 Clinical Trial
Key facts
- Who runs it
- R-Bio
- Where
- South Korea4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 129 people enrolled
- Started
- 13 Apr 2020
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional
- Treatments tested
- JOINTSTEM
- Record updated
- 10 July 2023
Who can take part
- Age
- 20 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Participants of Jointstem Phase 3 Clinical Trial
- Participates who signed informed consent document of this study
Who cannot take part
- No applicable
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this follow-up study is to investigate the efficacy and safety of autologous Adipose Tissue derived Mesenchymal stem cells (JOINTSTEM®) in patient with severe Knee Osteoarthritis.
The group in the trial
- JOINTSTEMTreatment being tested
Long Term Follow-up after Jointstem Transplantation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-Term Safety and Efficacy Extension Study Of Autologous Adipose-Derived Mesenchymal Stem Cells 『JOINTSTEM』 in Patients With Knee Osteoarthiritis: A Phase III Extension Study
- Publications
- Factors affecting outcomes of intra-articular injection of autologous, culture-expanded, adipose-derived mesenchymal stem cells in knee osteoarthritis.Stem cells translational medicine, 2026
- Record updated
- 10 July 2023